Table 3 Baseline characteristics of patients in each enrolled trial
Author (year) | No.a | Age (year, SD)a | Sex (Male, %)a | BMI (kg/m2, SD)a | Smoking (Pack-year, SD)a | Post-FEV1/FVC (%, SD)a | Post-FEV1 (L, SD)a | Post-FEV1 (%predicted, SD)a | Post-FVC (L, SD)a | |
|---|---|---|---|---|---|---|---|---|---|---|
Bredenbroker, 2002 | 169 | NM | NM | NM | NM | NM | NM | NM | NM | |
Boszormenyi-Nagy, 2005 | 200 | NM | NM | NM | NM | NM | NM | NM | NM | |
Rabe, 2005 | 555 | 64 (42 ~ 87) | 410 (75) | 26 (5.0) | 41 (20.6) | 50 (12) | 1.50 (0.48) | 54 (13.2) | 3.08 (0.85) | |
Calverley, 2007 | 760 | 65 (9.6) | 571 (75) | 25 (5.0) | 42 (22.9) | 40.3 (11.2) | 1.13 (0.04) | 41 (11.0) | NM | |
Calverley, 2009 | 1537 | 64 (9) | 1150 (75) | 25.8 (5.9) | 48 (25) | 42.3 (11.2) | 1.10 (0.4) | 36.1 (10.6) | NM | |
Fabbri, 2009 | M2-127 | 466 | 65 (9) | 319 (68) | NM | 43 (22) | 49.8 (9.4) | 1.51 (0.4) | 54.7 (9.1) | NM |
M2-128 | 371 | 64 (9) | 262 (71) | NM | 43 (22) | 52.7 (10.3) | 1.55 (0.5) | 56.0 (11.6) | NM | |
Lee, 2011 | 203 | 68 (41 ~ 91) | 188 (92.6) | 22.39 (3.7) | 42 (22.1) | 50.5 (11.8) | 1.41 (0.5) | 55.1 (16.5) | NM | |
Rennard, 2011 (M2-111) | 567 | 64 (8.7) | 387 (68.3) | 26.0 (5.7) | 50 (28.2) | 43.3 (10.1) | 1.12 (0.4) | 36.8 (10.7) | NM | |
Ferguson, 2012 | 1150 | NM | NM | NM | NM | NM | NM | NM | NM | |
O’Donnell, 2012 | 127 | 60 (9) | 93 (73.2) | 26.4 (5.0) | 41 (20) | 51 (11) | NM | 56 (12) | NM | |
Zheng, 2014 | 313 | 64.2 (8.76) | 283 (90.4) | 21.8 (3.42) | 37.2 (21.18) | 35.78 (9.69) | 0.95 (0.35) | 36.84 (11.42) | NM | |
Martinez, 2015 | 969 | 65 (8.4) | 718 (74) | 26.5 (5.47) | 48 (24.6) | 40.2 (10.81) | 1.1 (0.33) | 35.4 (9.25) | NM | |
Wells, 2015 | 11 | 62 (7) | 7 (64) | NM | 47 (26) | 53 (12) | NM | 45 (12) | NM | |